Five Prime Therapeutics has triggered a $5 million milestone payment for the first Investigational New Drug (IND) application to the U.S. Food and Drug Administration by Bristol-Myers Squibb for a therapeutic candidate under the immune checkpoint pathway discovery collaboration between the companies.    The first clinical candidate from the collaboration is a fully-human monoclonal antibody targeting TIM-3 (T-cell immunoglobulin and mucin domain-3), an immune checkpoint receptor that is ...